Article
Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405).
International journal of clinical oncology - 1 Sept 2022
Haratake Naoki, Shimokawa Mototsugu, Seto Takashi, Yoshioka Hiroshige, Yamamoto Nobuyuki, Nakagawa Kazuhiko, Mitsudomi Tetsuya
Abstract excerpt
BACKGROUND: Pemetrexed is common cytotoxic chemotherapy among non-squamous non-small cell lung cancer (non-Sq-NSCLC) patients; however, among epidermal growth factor receptor (EGFR)-positive lung cancer, there is no clear evidence to support the efficacy of sequential treatment with pemetrexed. MATERIAL AND METHODS: We performed a post-hoc analysis of subsequent chemotherapies among 144 patients who received the...
Topics
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Cisplatin
- Docetaxel
- ErbB Receptors
- Gefitinib
- Humans
- Lung Neoplasms
- Mutation
- Pemetrexed